Role of Lipoprotein Levels and Function in Atherosclerosis Associated with Autoimmune Rheumatic Diseases

Ronda, Nicoletta; Zimetti, F.; Adorni, Maria Pia; Palumbo, Maria Michela; Karpouzas, George; Bernini, Franco

doi:10.1016/j.rdc.2022.07.006

Cited by 3 publications

(1 citation statement)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apo(a) undergoes oxidation and partial proteolysis by metalloproteinases, which contribute to the development of an atheromatous plaque. Recent review publications, such as those by Mehta (2022) [402], Lu (2022) [403], Di Giovanni (2023) [404], Ronda (2023) [405], Bellot (2023) [406], Guo (2023) [407], Močnik (2023) [408], Kim (2023) [409], and Poznyak (2023) [410], have detailed the pathogenetic role of impaired Lp metabolism in atherogenesis. It has been shown that all Lp-containing apoB-100 is associated with atherosclerosis.…”

Section: Role Of Lipoprotein Metabolism Dysfunction In the Pathogenes...mentioning

confidence: 99%

Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes

Gusev

Sarapultsev

2023

IJMS

View full text Add to dashboard Cite

Recent advances have greatly improved our understanding of the molecular mechanisms behind atherosclerosis pathogenesis. However, there is still a need to systematize this data from a general pathology perspective, particularly with regard to atherogenesis patterns in the context of both canonical and non-classical inflammation types. In this review, we analyze various typical phenomena and outcomes of cellular pro-inflammatory stress in atherosclerosis, as well as the role of endothelial dysfunction in local and systemic manifestations of low-grade inflammation. We also present the features of immune mechanisms in the development of productive inflammation in stable and unstable plaques, along with their similarities and differences compared to canonical inflammation. There are numerous factors that act as inducers of the inflammatory process in atherosclerosis, including vascular endothelium aging, metabolic dysfunctions, autoimmune, and in some cases, infectious damage factors. Life-critical complications of atherosclerosis, such as cardiogenic shock and severe strokes, are associated with the development of acute systemic hyperinflammation. Additionally, critical atherosclerotic ischemia of the lower extremities induces paracoagulation and the development of chronic systemic inflammation. Conversely, sepsis, other critical conditions, and severe systemic chronic diseases contribute to atherogenesis. In summary, atherosclerosis can be characterized as an independent form of inflammation, sharing similarities but also having fundamental differences from low-grade inflammation and various variants of canonical inflammation (classic vasculitis).

show abstract

Section: Role Of Lipoprotein Metabolism Dysfunction In the Pathogenes...mentioning

confidence: 99%

Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes

Gusev

Sarapultsev

2023

IJMS

View full text Add to dashboard Cite

show abstract

Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology

Cacciapaglia,

Spinelli,

Erre

et al. 2024

European Journal of Internal Medicine

View full text Add to dashboard Cite

Unraveling the Pleiotropic Role of High‐Density Lipoproteins (HDLs) in Autoimmune Rheumatic Diseases

Giacaglia,

Pires,

Santana

et al. 2024

International Journal of Rheumatology

View full text Add to dashboard Cite

Autoimmune rheumatic diseases (ARDs) exhibit an elevated incidence of cardiovascular disease (CVD). The elevation of inflammatory and immune stress accompanying ARDs contributes to atherosclerosis development and alterations in lipid metabolism and lipoprotein profile add to cardiovascular (CV) risk. The plasma concentration of high‐density lipoprotein cholesterol (HDLc) is inversely related to CVD and serves as a discriminator of CV risk. However, this association is not unequivocal, and changes in HDL functionality appear to emerge as a better indicator of CV risk, albeit difficult to measure and monitor clinically. The modulation of HDLc itself can bring benefits in controlling autoimmunity and reducing ARD activity. Understanding HDL function and each peculiarity involved in ARDs enables to seek means to prevent ischemic outcomes associated with CVD, in the face of the residual CV risk persisting even with controlled disease activity and classic risk factors. By comprehending HDL’s structural and functional nuances, it will be possible to develop more effective strategies to manage the evolution and outcomes of ARDs. It is also necessary to standardize diagnostic methods and establish different markers for each specific disease allowing the design of intervention strategies to restore HDL functionality, reduce residual CV, and prevent, alleviate, or even suppress ARD activity.

show abstract

Role of Lipoprotein Levels and Function in Atherosclerosis Associated with Autoimmune Rheumatic Diseases

Cited by 3 publications

References 74 publications

Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes

Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes

Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology

Unraveling the Pleiotropic Role of High‐Density Lipoproteins (HDLs) in Autoimmune Rheumatic Diseases

Contact Info

Product

Resources

About